In summary, targeting PLK1 lead to a striking tumour regression in three out of fpur CCND1-driven PDX models, while AKT1 and mTOR mutated PDX preferably responded to AKT1 and mTOR inhibitors. The gene discussed is CCND1; the disease is neoplasm.